New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 22, 2014
07:08 EDTVIVO, EXAS, QDEL, DGX, ABAX, IDXXLife Sciences highlights this week at Canaccord
Canaccord highlighted six diagnostic names that report this week and recommends buying Top Pick IDEXX (IDXX) into the print given strong recurring razor/razorblade sales and consistent organic growth. The analyst expects Hold rated Quest Diagnostics (DGX) to report upside to Street estimates of $1.06/$1.882B, Quidel (QDEL) to have an uneventful report, Exact Sciences (EXAS) to provide an update on numerous catalysts near-term and Abaxis (ABAX) to report earnings below consensus. Lastly, the firm is cautious on Meridian Bioscience (VIVO) following a competitor report last week.
News For IDXX;DGX;EXAS;ABAX;QDEL;VIVO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 26, 2015
12:20 EDTQDELQuidel management to meet with Piper Jaffray
Subscribe for More Information
10:00 EDTDGXOn The Fly: Analyst Downgrade SummaryStarz
Subscribe for More Information
08:46 EDTVIVOMeridian Bioscience receives CE Mark for streptococcus pneumoniae test
Meridian Bioscience announces that it has received the CE Mark for its new test for Streptococcus pneumoniae. TRU STREP PNEUMO is a rapid, qualitative immunoassay for the detection of S. pneumo antigen in urine and CSF and will be distributed in the EMEA regions by Meridian Bioscience Europe and in additional international markets by the company’s global distribution network.
08:38 EDTVIVOMeridian Bioscience receievs CE mark for two molecular amplification tests
Meridian Bioscience announced that it has received the CE Mark for two new molecular diagnostic tests for Chlamydia trachomatis and Neisseria gonorrhoeae, the sixth and seventh assays on the illumigene platform. Along with these two new assays, Meridian also received the CE Mark for an innovative, simple, fast and cost effective sample preparation system, M-prep, that is designed to facilitate the isolation of Chlamydia and Gonorrhoeae from clinical samples. All three products will be distributed in the EMEA regions by Meridian Bioscience Europe and in additional international markets by the company’s global distribution network.
08:33 EDTVIVOMeridian Bioscience receives CE Mark for chlamydia, gonorrhoeae tests
Meridian Bioscience announced that it has received the CE Mark for two new molecular diagnostic tests for Chlamydia trachomatis and Neisseria gonorrhoeae, the sixth and seventh assays on the illumigene platform. Along with these two new assays, Meridian also received the CE Mark for a sample preparation system, M-prep, that is designed to facilitate the isolation of Chlamydia and Gonorrhoeae from clinical samples. All three products will be distributed in the EMEA regions by Meridian Bioscience Europe and in additional international markets by the company’s global distribution network.
07:24 EDTDGXQuest Diagnostics downgraded to Buy from Conviction Buy at Goldman
Goldman removed Quest Diagnostics (DGX) from the Conviction Buy List and added LabCorp (LH) to the list. The firm believes LabCorp will have higher average organic growth and earnings growth, and views its valuation as more attractive. The firm rates Quest Diagnostics a Buy with a $77 price target.
February 25, 2015
08:47 EDTEXASExact Sciences weakness creates buying opportunity, says JMP Securities
Subscribe for More Information
February 24, 2015
11:50 EDTEXASExact Sciences Q1 test guidance conservative, says Mizuho
Subscribe for More Information
08:50 EDTEXASExact Sciences management to meet with William Blair
Subscribe for More Information
07:32 EDTEXASExact Sciences reports Q4 EPS (38c), consensus (39c)
Subscribe for More Information
February 23, 2015
18:02 EDTEXASOn The Fly: After Hours Movers
Subscribe for More Information
17:14 EDTEXASWEDC to provide up to $9M in tax credits to Exact Sciences
Subscribe for More Information
09:59 EDTDGXOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Antofagasta (ANFGY) downgraded to Sell from Neutral at Goldman... Arch Coal (ACI) downgraded to Sell from Buy at Argus... BHP Billiton (BHP) downgraded to Equal Weight from Overweight at Morgan Stanley... Beazer Homes (BZH) downgraded to Neutral from Buy at Compass Point... Boeing (BA) downgraded to Sell from Neutral at Goldman... Century Communities (CCS) downgraded to Neutral from Overweight at JPMorgan... CyberArk (CYBR) downgraded to Underweight from Neutral at JPMorgan... DirecTV (DTV) downgraded to Hold from Buy at Brean Capital... Enerplus (ERF) downgraded to Hold from Buy at Desjardins... Fiserv (FISV) downgraded to Neutral from Buy at Monness Crespi... GP Strategies (GPX) downgraded to Neutral from Buy at B. Riley... Interactive Brokers (IBKR) downgraded to Market Perform at Keefe Bruyette... MRC Global (MRC) downgraded at BB&T... Precision Castparts (PCP) downgraded to Neutral from Buy at Goldman... Quest Diagnostics (DGX) downgraded at BofA/Merrill... Rio Tinto (RIO) downgraded to Equal Weight from Overweight at Morgan Stanley... Roth Capital downgraded Spectrum (SPPI) on court case loss... Royal Dutch Shell (RDS.A) downgraded to Sector Perform from Outperform at Howard Weil... Ryland Group (RYL) downgraded to Neutral from Buy at Compass Point... Salix (SLXP) downgraded to Market Perform from Outperform at Leerink... Standard Pacific (SPF) downgraded to Neutral from Buy at Compass Point... Superior Energy (SPN) downgraded to Neutral from Outperform at Credit Suisse... Transocean (RIG) downgraded to Negative from Neutral at Susquehanna... Vale (VALE) downgraded to Equal Weight from Overweight at Morgan Stanley.
08:18 EDTDGXQuest Diagnostics downgraded at BofA/Merrill
Subscribe for More Information
06:24 EDTDGXQuest Diagnostics downgraded to Underperform from Neutral at BofA/Merrill
February 20, 2015
07:08 EDTDGXAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
February 17, 2015
09:01 EDTDGXQuest Diagnostics, Genomic Vision renew collaboration for three years
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use